TY - JOUR
T1 - Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer
AU - Riess, Jonathan
AU - Logan, Aaron C.
AU - Krupitskaya, Yelena
AU - Padda, Sukhmani
AU - Clément-Duchne, Christelle
AU - Ganjoo, Kristen
AU - Colevas, A. Dimitrios
AU - Pedro-Salcedo, Melanie San
AU - Kuo, Calvin J.
AU - Wakelee, Heather A.
PY - 2012/3
Y1 - 2012/3
N2 - We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. We also examined TTP in relation to hemoglobin changes. Median hemoglobin increased significantly from a 12.9 g/dL pretreatment to 13.8 g/dL (p =.01) after the second cycle of maintenance bevacizumab until the first off cycle measurement. There was no difference in TTP in patients who achieved a rise in hemoglobin compared with patients who did not (median 238 days vs. 268 days, p =.38.) Maintenance bevacizumab is associated with increased hemoglobin in advanced, nonsquamous, NSCLC patients.
AB - We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. We also examined TTP in relation to hemoglobin changes. Median hemoglobin increased significantly from a 12.9 g/dL pretreatment to 13.8 g/dL (p =.01) after the second cycle of maintenance bevacizumab until the first off cycle measurement. There was no difference in TTP in patients who achieved a rise in hemoglobin compared with patients who did not (median 238 days vs. 268 days, p =.38.) Maintenance bevacizumab is associated with increased hemoglobin in advanced, nonsquamous, NSCLC patients.
KW - Angiogenesis
KW - Cancer biomarkers
KW - Clinical trials
KW - Non-small cell lung cancer
KW - VEGF
UR - http://www.scopus.com/inward/record.url?scp=84857616374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857616374&partnerID=8YFLogxK
U2 - 10.3109/07357907.2012.656862
DO - 10.3109/07357907.2012.656862
M3 - Article
C2 - 22360362
AN - SCOPUS:84857616374
VL - 30
SP - 231
EP - 235
JO - Cancer Investigation
JF - Cancer Investigation
SN - 0735-7907
IS - 3
ER -